Navigation Links
Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
Date:7/6/2010

DANBURY, Conn., July 6 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, U.S.A. next week.

Oral Presentation:

#51, Oral session on peptides and proteins, Monday July 12, 2010 4:00 PM (PT) "'Smart' Basal Insulin Formulation that Releases Insulin in Response to Blood Glucose Concentrations of Diabetic Swine," to be presented by N. Kashyap, Biodel Inc.

Poster Presentation:

#373, Poster session on peptides and proteins, Monday July 12, 2010 1:00 PM - 2:00 PM (PT) "Effect of EDTA Concentration on Ultra-Rapid Action of VIAject® in Diabetic Miniature Swine," to be presented by Dr. R. Pohl, Biodel Inc.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes.  Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs.  Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the FDA with a Prescription Drug User Fee Act action date of October 30, 2010.  Earlier-stage product candidates include VIAtab(TM), a sublingual tablet formulation of insulin, a line of basal insulins, and a stabilized formulation of glucagon. For further information regarding Biodel, please visit the company's website at www.biodel.com.


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
2. Biodel Inc. Completes Enrollment of Two Pivotal Phase III Clinical Trials of VIAject(TM) and Plans Manufacturing Facility for VIAject(TM)
3. Biodel Inc. Expands Ongoing Phase III VIAject(TM) Clinical Trials Into Europe
4. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
6. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
7. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
8. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
9. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
10. Sysmex America Announces Executive Leadership Changes
11. FUISZ Announces Advances in Devices and Solid Dosage Form
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... -- The vast majority of dialysis patients currently receive ... usually 3 times a week, with treatment times averaging ... equipment preparation and wait time.  This regimen can be ... who are elderly and frail.  Many elderly dialysis patients ... for some duration of time. Residents in ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to a ... new, often overlooked aspect of head lice: the parasite’s ability to live away from a ... occurrence, but a necessary one in the event that lice have simply gotten out of ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):